Pharmacovigilance and Scientific Data Curation: Protecting Patient Safety

Pharmacovigilance — the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects and other drug-related problems — depends fundamentally on the systematic collection, curation, and analysis of safety data from diverse sources. Scientific curators play an increasingly recognised role in pharmacovigilance operations, translating primary literature into structured safety information that supports regulatory decision-making and public health protection.

The Scientific Foundations of Pharmacovigilance

Pharmacovigilance operates on the recognition that the safety profile of a medicinal product cannot be fully characterised during pre-approval clinical trials, which are inherently limited in size, duration, and patient population diversity. Post-marketing surveillance through pharmacovigilance systems enables the detection of adverse drug reactions (ADRs) that are too rare, delayed, or confined to specific patient subgroups to be observed in pre-approval studies.

The scientific discipline draws on principles from epidemiology, biostatistics, clinical medicine, and information science. Signal detection — the identification of a new or changing drug-adverse event association that warrants further investigation — employs both quantitative disproportionality analysis of spontaneous reporting databases and qualitative literature review. The Medical Dictionary for Regulatory Activities (MedDRA) provides the standardised terminology used globally for coding adverse events in regulatory submissions and pharmacovigilance databases.

Sources of Pharmacovigilance Data

Pharmacovigilance data are derived from multiple complementary sources, each offering different strengths in terms of signal sensitivity, data quality, and population representativeness. Spontaneous adverse event reporting systems — exemplified by the FDA Adverse Event Reporting System (FAERS), the WHO VigiBase, and national Yellow Card schemes — constitute the primary real-world source of post-marketing safety signals. Despite their well-recognised limitations including under-reporting and reporting bias, spontaneous reporting systems have historically been responsible for detecting many of the most important post-marketing drug safety signals.

Published scientific literature, including case reports, case series, observational studies, and clinical trials, provides complementary safety information that is systematically captured through literature surveillance programmes. Scientific curators performing literature-based pharmacovigilance extract and code individual case safety reports from publications, translating narrative clinical descriptions into structured, MedDRA-coded safety data. Electronic health records and claims databases provide large-population observational data enabling epidemiological quantification of adverse event risks through formal pharmacoepidemiological study designs.

The Role of Scientific Curation in Safety Data Management

Scientific curation contributes to pharmacovigilance through the systematic identification and structured capture of adverse event information from published literature. The literature surveillance process involves systematic database searching across biomedical literature sources, screening retrieved publications for reportable adverse events using defined inclusion and exclusion criteria, and extracting case-level information including patient demographics, drug exposure details, adverse event descriptions, and clinical outcomes.

Extracted case information is coded using MedDRA terminology at the most clinically specific level appropriate for the described event, following the principle of lowest-level term coding that accurately represents the reported clinical finding. Multiple adverse events within a single case report are coded individually, enabling analysis of the complete adverse event profile associated with a given drug exposure. Data quality in literature-derived case reports is critically dependent on the scientific training and clinical comprehension of the curator, as clinical narratives in published literature vary considerably in completeness and terminology clarity.

Signal Detection and Assessment

Pharmacovigilance signal detection encompasses both qualitative and quantitative methods applied to accumulated safety data. Quantitative signal detection in spontaneous reporting databases employs disproportionality statistics — measures that compare the observed reporting frequency of a specific drug-event combination against an expected frequency derived from the reporting patterns of all other drugs in the database. Commonly applied metrics include the Proportional Reporting Ratio (PRR), the Reporting Odds Ratio (ROR), and the information component (IC) used in the WHO VigiBase system.

A detected signal represents a hypothesis requiring clinical and scientific evaluation rather than a confirmed causal relationship. Signal assessment involves expert clinical review of the biological plausibility of the association, the consistency of reports across different populations and settings, the temporal relationship between drug exposure and event onset, the availability of dechallenge and rechallenge information, and the presence of alternative explanations including underlying disease progression or concomitant medications.

Regulatory Implications of Pharmacovigilance Data

Pharmacovigilance findings inform regulatory actions across a spectrum of risk management measures proportionate to the severity and certainty of identified safety concerns. At the lower end of the spectrum, product label updates incorporating new adverse event information represent the most frequently applied regulatory response to emerging safety signals. More substantial signals may trigger Risk Evaluation and Mitigation Strategies (REMS) in the United States or Risk Management Plans (RMPs) under European regulatory frameworks, imposing prescribing restrictions, mandatory monitoring requirements, or patient communication programmes.

In the most serious circumstances, regulatory agencies may suspend or withdraw marketing authorisation for products where the benefit-risk balance is judged unfavourable in light of accumulated pharmacovigilance evidence. The scientific integrity of pharmacovigilance data curation directly influences the quality of these regulatory decisions, underscoring the patient safety significance of rigorous curation practice.